Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | TFPI | P10646 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | NPY4R | P50391 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521437 | 1.00 | EGFR (0.43) | EGFRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29357843 | 1.00 | EGFR (0.43) | EGFRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3208080 | 0.84 | FOLH1 (0.50) | EGFRFOLH1 | |
| SCHEMBL3208063 | 0.84 | FOLH1 (0.50) | EGFRFOLH1 | |
| SCHEMBL18862076 | 0.82 | NMT1 (0.55) | FURINNMT2NMT1NPY5RNPY1R | |
| SCHEMBL22674899 | 0.81 | FURIN (0.42) | FURINNMT2NMT1 | |
| SCHEMBL30140843 | 0.81 | EGFR (0.46) | EGFRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30608545 | 0.81 | NMT1 (0.52) | EGFRTFPINMT2NMT1 | |
| SCHEMBL31694511 | 0.81 | TFPI (0.52) | EGFRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30886175 | 0.80 | FOLH1 (0.49) | EGFRFURINNMT2NMT1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12366582-B2 | Collagen type X alpha-1 assay | NORDIC BIOSCIENCE A/S (DK) | 2025-07-22 | — | — | US | claimed |
| CN-117683090-A | Polypeptide targeting extracellular vesicles and bone marrow mesenchymal stem cells and application thereof | 中国人民解放军空军军医大学 | 2024-03-12 | — | — | CN | claimed |
| EP-3596120-B1 | COLLAGEN TYPE XVIII ASSAY | NORDIC BIOSCIENCE AS (DK) | 2023-12-13 | — | — | EP | claimed |
| US-20230340092-A1 | Collagen Type XVIII Assay | NORDIC BIOSCIENCE A/S (DK) | 2023-10-26 | — | — | US | claimed |
| US-20220146528-A1 | Collagen Type X Alpha-1 Assay | NORDIC BIOSCIENCE A/S (DK) | 2022-05-12 | — | — | US | claimed |
| CN-121294549-B | Polypeptide modified cationic polymer nanoparticle and preparation method and application thereof | 山东大学齐鲁第二医院 | 2026-02-17 | — | — | CN | disclosed |
| CN-121294549-A | Polypeptide modified cationic polymer nanoparticle and preparation method and application thereof | 山东大学齐鲁第二医院 | 2026-01-09 | — | — | CN | disclosed |
| US-20250367170-A1 | TOPICAL ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR TREATING EYE CONDITIONS | CLEVELAND CLINIC FOUND (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4638785-A1 | A PCR-ELISA ANALOGOUS ANTIBODY-FREE METHOD FOR DETECTING A TARGET NUCLEIC ACID IN A SAMPLE | Universität Heidelberg (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12366582-B2 | Collagen type X alpha-1 assay | NORDIC BIOSCIENCE A/S (DK) | 2025-07-22 | — | — | US | disclosed |
| WO-2025137654-A1 | ALLERGY VACCINE PLATFORM BASED ON SUPRAMOLECULAR MATERIALS | DUKE UNIVERSITY (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12331074-B2 | Site-specific serine ADP-ribosylated proteins and peptides and method for producing the same | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-06-17 | — | — | US | disclosed |
| WO-2023034779-A1 | TOPICAL DRUG TREATMENT TO PREVENT OR REDUCE CORNEAL SCARRING | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-19 | — | — | US | disclosed |
| WO-2022251457-A2 | COMPOSITIONS, METHODS, AND UTILITY OF CONJUGATED BIOMOLECULE BARCODES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-12-01 | — | — | WO | disclosed |
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-28 | — | — | US | disclosed |
| CN-112239505-B | Method for capturing recombinant anti-CD 171 octavalent antibody and nerve-derived exosome | 上海良润生物医药科技有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-20220146528-A1 | Collagen Type X Alpha-1 Assay | NORDIC BIOSCIENCE A/S (DK) | 2022-05-12 | — | — | US | disclosed |
| WO-2022066580-A1 | RAF DEGRADING COMPOUNDS | KINNATE BIOPHARMA INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-114177199-A | Polypeptide-modified gold cluster and application of polypeptide-modified gold cluster in resisting tumor invasion and metastasis by inhibiting activity of cathepsin B | 北京工业大学 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | PIK3CA, PIK3CB, AKT3 | EGFR 386/4885GRIN2D 3729/4885GRIN3B 2976/4885 |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, PIK3CB, AKT3 | EGFR 386/4885GRIN2D 3729/4885GRIN3B 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.